Background According to expert consensus, the time interval between Hymenoptera venom
immunotherapy (VIT) injections can be extended up to 12 weeks, without significant impact …

During the ongoing pandemic of Coronavirus Disease 2019 (COVID-19) allergic patients
need to continue their constant and proper treatment, including allergen-specific …

The population prevalence of insect venom allergy ranges between 3–5%, and it can lead to
potentially life-threatening allergic reactions. Patients who have experienced a systemic …

One hundred and ninety-seven patients (67.5%) were being treated with I Vespula i spp
venom immunotherapy, 87 patients (29.8%) with I Apis mellifera i venom, and only 8 patients …

Background Allergen-specific immunotherapy (AIT) is accepted as the only disease-
modifying therapy for IgE-mediated allergic airway diseases and hymenoptera venom …

Background Current literature is inconsistent regarding the risk of severe side effects using
accelerated induction protocols in Hymenoptera venom immunotherapy (VIT). In addition …

Introduction: Hymenoptera venom allergy is associated with significant morbidity and
deterioration in health-related quality of life, and risk of fatal systemic reactions. Although …

Abstract To the Editor, The COVID-19 pandemic led to rapid changes to our clinical and
educational activities, showing that most of care of allergic diseases could be delayed with …

Background: Misdiagnosed vaccine-related “allergies” lead to unnecessary vaccine
deferrals and incomplete vaccinations, leaving patients unprotected against COVID-19. To …

The vaccination campaign against the Severe acute respiratory syndrome coronavirus 2
(Sars-Cov-2) started on 8 December 2020 in UK, after the approval of BNT162b2 by the …